Search results for "Lipoprotein (a)"

showing 10 items of 57 documents

Left ventricular diastolic function and cardiometabolic factors in obese normotensive children

2014

Abstract Background and aim Left ventricular (LV) hypertrophy and diastolic function have been found to be associated with obesity and hypertension in adults. However, there are scarce data about the association of obesity itself to cardiac alteration in children. The aim of this study was to detect early changes in LV structure and function in obese children and whether they are associated with the biomarkers of metabolic risk and endothelial activation. Methods and results A total of 130 children aged 7–16 years (88 obese and 42 normal-weight children) were studied. All children had normal resting blood pressure. Two-dimensional ultrasound with M-mode imaging was performed to assess the L…

Malemedicine.medical_specialtyMean arterial pressureAdolescentHeart VentriclesEndocrinology Diabetes and MetabolismDiastoleVascular Cell Adhesion Molecule-1Medicine (miscellaneous)Left ventricular hypertrophyBody Mass IndexMuscle hypertrophyEndothelial activationVentricular Dysfunction LeftRisk FactorsInternal medicinemedicineHumansMass indexObesityProspective StudiesChildUltrasonographyMetabolic SyndromeNutrition and DieteticsApolipoprotein A-Ibusiness.industrymedicine.diseaseCross-Sectional StudiesEarly DiagnosisBlood pressureSolubilityCardiovascular DiseasesSpainCardiologyFemaleCardiology and Cardiovascular MedicinebusinessRetinol-Binding Proteins PlasmaBody mass indexBiomarkersNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Effect of walnut-enriched meat on the relationship between VCAM, ICAM, and LTB4 levels and PON-1 activity in ApoA4 360 and PON-1 allele carriers at i…

2011

Cardiovascular risk depends largely on paraoxonase (PON-1) and apolipoprotein A4 (APOA4) gene polymorphisms. To compare the effects of consumption of walnut-enriched meat versus low-fat meat (LM) on selected soluble adhesion molecules and leukotrienes (LTB4). In all 22 subjects at increased cardiovascular risk were taken. It is a non-blinded, cross-over, placebo-controlled study. Two 5-week experimental periods separated by 4–6 week wash-out interval. Participants consumed walnut-enriched meat during one period and LM during the other. Diet characteristics, HDLc, Apo A1, paraoxonase, sVCAM-1, sICAM-1 and LTB4 were analysed. PON-1 55, PON-1 192 and APOA4 360 polymorphism effects were also as…

Malemedicine.medical_specialtyMeatApolipoprotein BLeukotriene B4Vascular Cell Adhesion Molecule-1Medicine (miscellaneous)JuglansLeukotriene B4APOA4chemistry.chemical_compoundRisk FactorsPolymorphism (computer science)Internal medicinemedicineHumansNutsAlleleRisk factorApolipoproteins APolymorphism GeneticNutrition and DieteticsApolipoprotein A-IbiologyAryldialkylphosphataseCholesterol HDLParaoxonaseMiddle AgedIntercellular Adhesion Molecule-1DietEndocrinologyEicosanoidchemistryCardiovascular DiseasesFood Fortifiedbiology.proteinFemalePlant PreparationsInflammation MediatorsCell Adhesion MoleculesEuropean Journal of Clinical Nutrition
researchProduct

Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia.

1995

A randomized double-blind study was carried out with gemfibrozil (600 mg b.i.d.) vs placebo in 20 patients (twelve males and eight females, age 52 +/- 3 years, BMI 24.2 +/- 0.4) suffering from primary hypertriglyceridemia (Fredrickson's type IV). Each group was treated for a 12 week period with gemfibrozil (n = 10) or placebo (n = 10) patients) in a double-blind fashion. Total cholesterol, HDL-cholesterol (HDL-C) and its subfractions (HDL2-C and HDL3-C), blood glucose, Apolipoproteins A1 and B, fibrinogen, plasminogen, factor VII, t-PA:Ag and PAI activity pre- and post-venous occlusion (VO) were determined. In the gemfibrozil-treated group a significant decrease of total cholesterol and tri…

Malemedicine.medical_specialtymedicine.medical_treatmentLipoproteinsFibrinogenchemistry.chemical_compoundDouble-Blind MethodInternal medicineFibrinolysismedicineGemfibrozilHumansTriglyceridesApolipoproteins BHypertriglyceridemiaTriglycerideApolipoprotein A-Ibusiness.industryCholesterolFibrinolysisHypertriglyceridemiaReverse cholesterol transportCholesterol HDLFibrinogenPlasminogenHematologyGeneral MedicineFactor VIIMiddle Agedmedicine.diseaseEndocrinologyCholesterolchemistryTissue Plasminogen Activatorlipids (amino acids peptides and proteins)FemaleGemfibrozilbusinessLipoproteinmedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Human apolipoprotein A-I natural variants: molecular mechanisms underlying amyloidogenic propensity

2012

Human apolipoprotein A-I (apoA-I)-derived amyloidosis can present with either wild-type (Wt) protein deposits in atherosclerotic plaques or as a hereditary form in which apoA-I variants deposit causing multiple organ failure. More than 15 single amino acid replacement amyloidogenic apoA-I variants have been described, but the molecular mechanisms involved in amyloid-associated pathology remain largely unknown. Here, we have investigated by fluorescence and biochemical approaches the stabilities and propensities to aggregate of two disease-associated apoA-I variants, apoA-IGly26Arg, associated with polyneuropathy and kidney dysfunction, and apoA-ILys107-0, implicated in amyloidosis in severe…

ProteomicsProtein Foldinglcsh:MedicineProtein aggregationpolymyxinsBiochemistryProtein Structure SecondaryMiceProtein structureneutrophilsMolecular Cell Biologypolycyclic compoundslcsh:ScienceCellular Stress ResponsesMultidisciplinaryProtein StabilityAmyloidosisCiencias QuímicasfluorescenseCell biologymacrophagesBiochemistryToxicityMedicineProtein foldinglipids (amino acids peptides and proteins)medicine.symptomPolyneuropathyResearch ArticleProtein StructureMedicinaLipoproteinsImmunologyBiophysicsInflammationAmyloidogenic ProteinsBiologyProtein ChemistryMicrobiologyCell Lineprotein aggregationmacrophage activationmedicineAnimalsHumansoligomersProtein InteractionsBiologyInflammationamyloidosisApolipoprotein A-IMacrophageslcsh:RImmunityProteinsnutritional and metabolic diseasesmedicine.diseaseApolipoproteinsAmino Acid SubstitutionCell cultureinflammationCiencias Médicaslcsh:QClinical ImmunologyMutant ProteinspolyneuropathyProtein Multimerization
researchProduct

A potential link between serum low-density lipoproteins and asthma

2015

Pulmonary and Respiratory MedicineHypersensitivity ImmediateMaleApolipoprotein A-Ibusiness.industryCholesterol HDLSettore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care Medicinemedicine.diseaseAsthmaText miningForced Expiratory VolumeImmunologyLow densityMedicineFemaleApolipoprotein A-I; Asthma; Cholesterol HDL; Female; Humans; Hypersensitivity Immediate; Male; Forced Expiratory VolumebusinessLink (knot theory)AsthmaHuman
researchProduct

Immunonephelometric determination of the apolipoprotein A-II.

1989

A fully mechanized immunonephelometric method is described for the rapid and specific determination of apolipoprotein A-II in serum. The method utilizes commercially available sheep antiserum against human apolipoprotein A-II. Nephelometry was performed with the Behring Nephelometer Analyzer (BNA). A single determination can be performed in 12 minutes, requiring 10 microliters sample volume. The measuring range is about 0.08 to 1.25 g/l apolipoprotein A-II. Precision is characterized by intra-assay coefficients of variation of 3.37%, 3.93% and 4.49% for apolipoprotein A-II concentrations of 1.22 g/l, 0.376 g/l and 0.185 g/l, and inter-assay coefficients of variation of 4.27% for an apolipop…

Radial immunodiffusionChromatographyApolipoprotein BbiologyChemistryHuman apolipoproteinBiochemistry (medical)Clinical BiochemistryApolipoprotein A-IIeducationGeneral MedicineSample volumeEvaluation Studies as TopicNephelometry and Turbidimetrybiology.proteinImmunologic TechniquesHumansNephelometryApolipoprotein A-IIApolipoproteins AJournal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie
researchProduct

Apolipoprotein A1 in Cerebrospinal Fluid Is Insufficient to Distinguish Alzheimer's Disease from Other Dementias in a Naturalistic, Clinical Setting.

2020

Apolipoprotein A1 (ApoA1) is the major protein component of the high-density lipoprotein and involved in cholesterol transport. Disruption of cholesterol homeostasis has been identified as a contributing factor for Alzheimer's disease (AD). Moreover, polymorphisms of ApoA1 have been associated with higher risk of disease onset and cognitive decline. Therefore, ApoA1 has been suggested as a biomarker in AD. Here, we tested a small cohort of AD and non-AD dementia patients and measured levels of ApoA1 in cerebrospinal fluid. Our results indicate that ApoA1 might not be applicable to distinguish AD from other forms of dementia.

Short CommunicationDiseasecerebrospinal fluidchemistry.chemical_compoundmedicineDementiaCognitive declinebiologyCholesterolbusiness.industryGeneral Neurosciencemedicine.diseasePsychiatry and Mental healthClinical PsychologychemistryCohortImmunologybiology.proteinBiomarker (medicine)biomarkerApolipoprotein A1lipids (amino acids peptides and proteins)Apolipoprotein A1Geriatrics and GerontologybusinessAlzheimer’s diseaseLipoproteindementiaJournal of Alzheimer's disease reports
researchProduct

Anti-inflammatory Function of High-Density Lipoproteins via Autophagy of IκB Kinase

2015

Background & Aims: Plasma levels of high-density lipoprotein (HDL) cholesterol are frequently found decreased in patients with inflammatory bowel disease (IBD). Therefore, and because HDL exerts anti-inflammatory activities, we investigated whether HDL and its major protein component apolipoprotein A-I (apoA-I) modulate mucosal inflammatory responses in vitro and in vivo. Methods: The human intestinal epithelial cell line T84 was used as the in vitro model for measuring the effects of HDL on the expression and secretion of tumor necrosis factor (TNF), interleukin-8 (IL-8), and intracellular adhesion molecule (ICAM). Nuclear factor-κB (NF-κB)-responsive promoter activity was studied by …

WT wild typeApolipoprotein BEMSA electrophoretic mobility shift assayMPO myeloperoxidaseIκB kinaseDSS dextran sodium sulphatemTOR the mammalian target of rapamycinRT-PCR real-time polymerase chain reactionNF-κBchemistry.chemical_compound540 ChemistryApoA-I apolipoprotein A-I10038 Institute of Clinical ChemistryOriginal ResearchTNF tumor necrosis factorbiologyIBD inflammatory bowel diseaseChemistryGastroenterologyMyeloperoxidase10076 Center for Integrative Human PhysiologyMEICS murine endoscopic index of colitis severityTumor necrosis factor alphalipids (amino acids peptides and proteins)3-MA 3-methyl adenineNF-κB nuclear factor κBHDL high-density lipoproteinLC3II light chain 3 IIPBS phosphate-buffered salinep-IKK phosphorylated IκB kinase610 Medicine & healthICAM intracellular adhesion molecule246-Trinitrobenzenesulfonic acidTg transgenicmedicineAutophagyCD Crohn’s disease2715 GastroenterologyColitislcsh:RC799-869KO knockoutHepatologyApolipoprotein A-IAutophagyInflammatory Bowel DiseaseTNBS 246-trinitrobenzenesulfonic acidmedicine.diseaseMolecular biologyIL interleukinsiRNA small interfering RNAPI-3 phosphatidylinositol-3Immunologybiology.protein2721 Hepatologylcsh:Diseases of the digestive system. GastroenterologyPFA paraformaldehydeLipoproteinDAPI 4′6-diamidino-2-phenylindoleCMGH Cellular and Molecular Gastroenterology and Hepatology
researchProduct

Dysfunctional High-Density Lipoproteins Are Associated With a Greater Incidence of Acute Coronary Syndrome in a Population at High Cardiovascular Risk

2020

Background: Studies have failed to establish a clear link between high-density lipoprotein (HDL) cholesterol and cardiovascular disease, leading to the hypothesis that the atheroprotective role of HDL lies in its biological activity rather than in its cholesterol content. However, to date, the association between HDL functional characteristics and acute coronary syndrome has not been investigated comprehensively. Methods: We conducted a case-control study nested within the PREDIMED (Prevención con Dieta Mediterránea) cohort, originally a randomized trial in which participants followed a Mediterranean or low-fat diet. Incident acute coronary syndrome cases (N=167) were individually matched …

high-density lipoproteinsMalemedicine.medical_specialtyAcute coronary syndromePopulationDysfunctional familyDisease030204 cardiovascular system & hematologyDiet Mediterraneanacute coronary syndrome03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSphingosineHDL cholesterolPhysiology (medical)Internal medicinemedicineHumans030212 general & internal medicineHigh-density lipoproteinseducationAgededucation.field_of_studyApolipoprotein A-ICholesterolbusiness.industryIncidence (epidemiology)Middle Agedmedicine.diseasechemistryCase-Control StudiesNested case-control studyCardiologyFemalelipids (amino acids peptides and proteins)Acute coronary syndromeLysophospholipidsLipoproteins HDLCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesLipoproteinCirculation
researchProduct

An evaluation of RVX-208 for the treatment of atherosclerosis

2015

Introduction: RVX-208 is a first-in-class, orally active, novel small molecule in development by Resverlogix Corporation (Calgary, AB, Canada). It acts through an epigenetic mechanism by inhibiting the bromodomain and extraterminal (BET) family of proteins, increasing apolipoprotein A-I (apoA-I) and targeting high-density lipoprotein (HDL) metabolism, including generating of nascent HDL and increased larger HDL particles, resulting in the stimulation of reverse cholesterol transport. RVX-208 also has a beneficial effect on inflammatory factors known to be involved in atherosclerosis and plaque stability. New therapeutic strategies are needed for patients with atherosclerosis.Areas covered: …

medicine.medical_specialtyApolipoprotein Bapolipoprotein A-IRVX 208high-density lipoproteinPharmacologyEpigenesis Geneticchemistry.chemical_compoundatherosclerosiHigh-density lipoproteinMetabolic DiseasesInternal medicinemedicineAnimalsHumansPharmacology (medical)QuinazolinonesPharmacologybiologyAnimalCholesterolMedicine (all)Cholesterol HDLReverse cholesterol transportRVX-208QuinazolineGeneral MedicineAtherosclerosisPlaque AtheroscleroticMetabolic DiseaseBromodomainOrally activeEndocrinologyhigh-density lipoprotein particlechemistryQuinazolinesbiology.proteinlipids (amino acids peptides and proteins)HumanLipoproteinExpert Opinion on Investigational Drugs
researchProduct